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This presentation contains forward-looking statements that are based on management’s current expectations and beliefs and are subject to a
number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described. All statements, other than
statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins,
capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and
prescriber patterns or practices, reimbursement activities and outcomes and other such estimates and results. Forward-looking statements involve
significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission (SEC)
reports filed by Amgen, including Amgen’s most recent annual report on Form 10-K and most recent periodic reports on Form 10-Q and Form 8-K.
Please refer to Amgen’s most recent Forms 10-K, 10-Q and 8-K for additional information on the uncertainties and risk factors related to our
business. Unless otherwise noted, Amgen is providing this information as of November 18, 2010, and expressly disclaims any duty to update
information contained in this presentation.
No forward-looking statement can be guaranteed and actual results may differ materially from those we project. The Company’s results may be
affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments
(domestic or foreign) involving current and future products, sales growth of recently launched products, competition from other products (domestic
Provided May 22 2012, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary materially;
Amgen disclaims any duty to update.
or foreign), difficulties or delays in manufacturing our products. In addition, sales of our products are affected by reimbursement policies imposed by
third-party payors, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and
guideline developments and domestic and international trends toward managed care and health care cost containment as well as U.S. legislation
affecting pharmaceutical pricing and reimbursement. Government and others’ regulations and reimbursement policies may affect the development,
usage and pricing of our products. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by
domestic and foreign government regulatory authorities. We or others could identify safety, side effects or manufacturing problems with our
products after they are on the market. Our business may be impacted by government investigations, litigation and products liability claims. Further,
while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged,
invalidated or circumvented by our competitors. We depend on third parties for a significant portion of our manufacturing capacity for the supply of
certain of our current and future products and limits on supply may constrain sales of certain of our current products and product candidate
development. In addition, we compete with other companies with respect to some of our marketed products as well as for the discovery and
development of new products. Discovery or identification of new product candidates cannot be guaranteed and movement from concept to product
is uncertain; consequently, there can be no guarantee that any particular product candidate will be successful and become a commercial product.
Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers.
This presentation includes GAAP and non-GAAP financial measures. In accordance with the requirements of SEC Regulation G, reconciliations
between these two measures, if these slides are in hardcopy, accompany the hardcopy presentation or, if these slides are delivered electronically,
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Provided May 22 2012, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary materially;
Amgen disclaims any duty to update.
• Boston based company focused on biologics for cancer and infectious disease
– Founded in 1999 at UCL; Opened US site in 2005
– Acquired by Amgen March 2011
• Lead product talimogene laherparepvec (formerly OncoVEXGM-CSF) 
– Activity demonstrated in multiple tumor types
BioVex Overview
Provided May 22 2012, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary materially;
Amgen disclaims any duty to update.
– Phase 3 melanoma study commenced in 2009
– Recruitment completed July 2011
• ImmunoVEXHSV2
– Live attenuated vaccine for genital herpes
– Dosing in Phase 1 trial commenced in 2010
Liu et al., Gene Therapy 2003
CMC challenges of an Oncolytic Immunotherapy 
• How does talimogene laherparepvec work?
• Does talimogene laherparepvec work?
• Bio-safety challenges in manufacturing a live viral product
- Pre-clinical safety challenges with a viral product
Provided May 22 2012, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary materially;
Amgen disclaims any duty to update.
- Manufacturing bio-safety
- Assuring viral safety of the product 
• Manufacturing challenges of live viral production
• Analytical challenges of a product with a dual mode of action
Innovative Mechanism of Action
Provided May 22 2012, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary materially;
Amgen disclaims any duty to update.
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Evidence of Destruction of Un-Injected Tumors
Provided May 22 2012, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary materially;
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injected tumors un-injected tumors
Liu et al., Gene Therapy 2003
pre-injection 2 days post injection
Evidence of Tumor Necrosis
Provided May 22 2012, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary materially;
Amgen disclaims any duty to update.
7 days post injection 6 weeks post injection




PFU / swab 
Replicates in the Tumor
Provided May 22 2012, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary materially;




3d 4d 5d 6d 7d 8d 9d 10d
Days post dose of 107 PFU/mL on day 0
Hu et al., Clin Cancer Res 2006
Evidence of Tumor Necrosis
melanoma, three injections : 106,108,108 pfu/ml
Provided May 22 2012, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary materially;
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BioVex and Amgen data on file
• Patient biopsies showed necrosis, all with strong HSV staining
• Unlike studies with previous oncolytic viruses, staining was spread throughout the tumor
• HSV staining was only rarely seen in non-necrotic tumor tissue and even more rarely in non-tumor 
tissue
Evidence of Tumor Selectivity
Provided May 22 2012, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary materially;
Amgen disclaims any duty to update.
Breast cancer                     Melanoma              Head & neck cancer




relative mRNA levels at 48 hours
Local Production of  GM-CSF in Tumor
Provided May 22 2012, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary materially;




low dose              mid dose
treatment group 
Hu et al., Clin Cancer Res 2006
Example of Results Observed from Melanoma Trial
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BioVex and Amgen data on file
Example of Results Observed in Melanoma Trial : Uninjected Sites
Provided May 22 2012, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary materially;
Amgen disclaims any duty to update.
Baseline                      8 Months                     









Right Shoulder – Baseline and 6 months












Provided May 22 2012, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary materially;
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(all pts and all stage IV)
- 40% (M1c)
- 93% (responders)
Senzer et al. JCO 2009;27:5763-5771
Safety challenges in manufacturing a 
live viral product
- Pre-clinical safety challenges with a viral product
- Manufacturing bio-safety
- Assuring viral safety of the product 
CMC issues in manufacturing a live virus product
• Design and Construction of a safe virus 
• Pre-clinical safety challenges with a viral product
• Manufacturing bio-safety
Provided May 22 2012, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary materially;
Amgen disclaims any duty to update.
• Assuring viral safety of your product 




Manufacturing process 1 2 3
At which point in the project do you focus on Bio-safety?
Provided May 22 2012, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary materially;
Amgen disclaims any duty to update.




• Causes cold sores, genital herpes
• Same family as VZV, EBV, CMV
• Extremely well characterised
• Pathology well understood
• Can replicate in most dividing cells
• Large non-integrating DS DNA genome
Why select Herpes simplex virus ‘HSV?’
Provided May 22 2012, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary materially;
Amgen disclaims any duty to update.
• Possible to accommodate large
genetic inserts
• Pre-existing immune response does not block reimmunisation
• Replication halted by acyclovir
• Known mutations supply tumour-
specific growth
• Tumor selective replication
– Delete ICP 34.5
• Enhance replication in tumors
– Engineer clinical isolates of HSV
– Increase US11 expression
• Increase systemic immune effects
Construction of a safe and effective Oncolytic virus
Provided May 22 2012, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary materially;
Amgen disclaims any duty to update.




• Selection of pre-clinical efficacy models – challenges of a human virus
• GLP toxicology - selection of suitable animal model and strain
- use in combination studies (chemo-radiation)
- use to support process changes
- Murine vs human GM-CSF
• Biodistribution - requires high sensitivity & specificity from qPCR assay
- special tissue handling methods
- key to designing clinical protocol and human distribution studies
Provided May 22 2012, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary materially;
Amgen disclaims any duty to update.
• Potential of latency and virus reactivitation
- poor laboratory models
• Cell bank and virus seed stock testing
• Virus characterisation and sequencing
• Proof of concept for viral safety features 
- tumour specificity
- GM-CSF production and distribution
- virus shedding
CMC challenges in manufacturing a live 
viral product
- Manufacturing challenges of live viral production
- Analytical challenges of a product with a dual mode of action
- Regulatory considerations for an oncolytic virus
Manufacturing Bio-safety
 Design of Manufacturing facility
- Early development : Multi use CMO & filling facilities
- Later development & commercial : custom design single use facility
- Use pressure cascade to contain and protect product
 Process design
- Low pressure to minimise spills and aerosols
- Risks increase with increasing volume
Provided May 22 2012, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary materially;
Amgen disclaims any duty to update.
- Minimise shear forces
- Maximise disposable use
- Terminal filtration vs asceptic processing
 Operator safety and training
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Viral safety when your product is a live virus
• Follow standard ICH/Ph.Eur/FDA guidelines
• Raw material testing
• Cell bank and Viral bank testing (MCB, WCB, MVSS, WVSS)
• Clinical batch testing at virus harvest stage
testing vs protection of product
in vitro adventitious testing on reporter cell lines*
Provided May 22 2012, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary materially;
Amgen disclaims any duty to update.
in vivo adventitious testing*
retroviral testing*
* impossible without good blocking antisera and dilution
• Mycoplasma testing*
Analytical challenges of a dual mode of action
Characterisation
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Herpes Simplex Virus (HSV)
• large, double stranded DNA virus (150Kb genome) 
• virus particle diameter 180 – 200 nm
• encodes for almost 80 proteins 
• virus particles composed of 4 structural elements
( 11 glycoproteins, 2 non-
Provided May 22 2012, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary materially;
Amgen disclaims any duty to update.






glyco proteins, lipid bilayer)
Batch release testing for Immunotherapy 
- the challenges
• Immunotherapy products may have more than one mode of action
Potency Assay (s)
Infectivity (Plaque assay)
GM-CSF assay of biological activity
• Purity
Intact Particle (SEC)
Dissociated Proteins (Coomassie gel/ HSV Western Blot)
Provided May 22 2012, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary materially;
Amgen disclaims any duty to update.
• Impurities
BSA, Benzonase® 
Inactive HSV, host cell DNA
Host cell protein
• Content
Total Protein (Protein Assay)




Product characterisation - How do you manage process change? 
• Can you demonstrate comparability for immunotherapeutics?
• Animal preclinical studies - safety 
- efficacy
• In vitro growth curves
• Tumour cell killing
• Potency bioassay
Provided May 22 2012, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary materially;
Amgen disclaims any duty to update.
• Physical characterisation (SEC, light scattering, density gradients, EM)
• Protein characterisation (SDS Page, MAb binding, western blots, 
sequencing, ELISA)
• DNA characterisation (sequence, fingerprint, qPCR)
• Comparison of impurities
• Accelerated stability studies (elevated temperatures & freeze thaw 
cycles)
A20 Tumour Model 



































































Provided May 22 2012, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary materially;









































































































































































Zetasizer Analysis – Particle Size
Particle Size Distribution Curves
Provided May 22 2012, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary materially;

















CBR#0503A DS CBR#0508A DS CBR#0510A DS
SD#5 DS SD#6 DS BP0841 DS
Dissociated Protein Quantitation
2D PAGE
• Clean images with distinct spots
• Spot pattern visually similar 
between batches
Provided May 22 2012, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary materially;
Amgen disclaims any duty to update.
• Quantitative analysis 
CMC Challenges of a Oncolytic Immunotherapy
• Increased expectation of purity & safety
• Increased expectation of consistency
• Complexity of characterisation
Conclusions
Provided May 22 2012, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary materially;




• Small scale production
The CMC challenges in 
Developing an Oncolytic
Immunotherapy
Colin Love, 
VP, Clinical Operations
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